A tissue scaffold includes a first film having a plurality of cell openings and a second film adjacent the first film and having a plurality of cell openings larger than the cell openings of the first film. The cell openings of the first film interconnect with the cell openings of the second film to define pathways extending through the first and second films.

Thermal memory springs may form arches, or have coils or spring arms and truss arms that expand from a relaxed state when the thermal memory springs warm to a temperature that is about the body temperature of a human being. The thermal memory springs may be used to expand interbody implants from a compact state into an expanded state once the implant has been inserted into the desired location within the body and the thermal memory springs that form a part of the implant warms to body temperature. Ends of the expanded thermal memory spring may contact a bone surface, thereby being an anti-expulsion edge.

A bone void plug includes a plug body that extends along a longitudinal axis between a proximal face and a distal opening and a recessed opening that extends from the distal opening toward the proximal face. The recessed opening is configured to receive a bone void filler.

An artificial functional spinal unit including an expandable intervertebral implant that can be inserted via a posterior surgical approach and used with one or more facet replacement devices to provide an anatomically correct range of motion is described. Lordotic and non-lordotic expandable, articulating implants and cages are described, along with embodiments of facet replacement devices and instruments for insertion. Methods of insertion are also described.

Method and set of surgical instruments for fitting a shoulder prosthesis, and the shoulder prosthesis. The proposed method seeks to interpose a bone graft between the previously prepared glenoid surface (G) of a scapula (S) of a patient's shoulder and the face of a glenoid prosthetic component opposite the articular surface. The set of instruments permit the bone graft to be taken from the upper epiphysis of the humerus (H), either in situ or ex vivo.

The present application relates to a facet joint prosthesis comprising a first component having a first disc with a first outer face for engagement of a first bone. The first outer face has an opposed first inner face, which includes a first post connecting said first disc to a tongue. The facet joint prosthesis further comprises a second component having a second disc with a second outer surface for engagement with a second bone. The second outer surface has an opposed second inner face, which comprises a bridge located near the periphery of said second disc. Said bridge connects the second disc with a third disc. The third disc comprises a pocket. Insertion of said tongue into said pocket and rotation of said tongue relative to said pocket results in a locking of said tongue between said second disc and said third disc.

The present invention relates to a bone implant comprising a porous body comprising particles of bioactive glass having a particle size of at least 500 m, wherein the composition of the bioactive glass is 45-59 weight-% of SiO.sub.2, 18-25 weight-% of Na.sub.2O, 17-25 weight-% of CaO and 0.1-6 weight-% of P.sub.2O.sub.5, and a film having a thickness of 10 m-200 m, made of a biocompatible polymer and arranged at least partially around the body.

An artificial knee joint 1 includes: an insert member 2 embedded in a part of a joint surface of a medial condyle MC or lateral condyle LC of a tibia T; and a bridge member 3 disposed underneath the insert member 2, and having a length that allows both ends thereof to be anchored to a cortical bone of a tibia T.

A bone implant composition and methods thereof include bone material made into various implant shapes including a cylinder having an outermost layer and an inner layer completely surrounded by the outermost layer. The bone implant compositions and methods include a bag or cylindrical tube made from a bone material which may be filled with additional bone material.

A pharmaceutical composition for treating moderate or severe rosacea comprises a formulated, body weight-independent low dose of minocycline that reduces the severity of rosacea in at least 2 weeks with a decrease in lesion count, Investigator's Global Assessment (IGA) score, and Clinician's Erythema Assessment (CEA) score with a measured improvement in quality of life.